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This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. It is a result of 3 hours of work and is not intended to be a comprehensive summary 
of available evidence on COVID-19 but aims to make original documents easily accessible to 
decision makers which, if relevant to them, they should go to before making decisions.   
 




















 COVID-19 predominantly 
involved the lungs in 11 
deceased patients with 
COVID-19 in this small 
prospective autopsy study, 
causing diffuse alveolar 
damage (DAD) and acute 
respiratory insufficiency 
 Death may be caused by the 
thrombosis observed in 
segmental and subsegmental 
pulmonary arterial vessels 
despite the use of 
prophylactic anticoagulation 
13.05.2020 Multiorgan and 




 In this autopsy series of 27 
patients, authors found 
SARS-CoV-2 had a 
organotropism beyond the 
respiratory tract, including the 
kidneys, heart, liver and brain 
 Authors speculate that 
tropism influences the course 
























WHO | Article 
 A phone-based survey was 
administered to a sample of 909 
households in Cox’s Bazar drawn 
from a household panel 
representative of Rohingya 
refugees and the host population 
 24.6% of camp residents and 
13.4% of those in host 
communities reported at least one 
common symptom of COVID-19 
 Among those seeking treatment 
42.3% in camps and 69.6% in 
host communities did so at a 
pharmacy 
 76.7% of those in camps and 
52.2% of those in the host 
community had attended a 
communal prayer in the previous 
week and another 47.4% in 
camps and 34.4% in the host 
community had attended a non-
religious social gathering 
 COVID-19 symptoms are highly 
prevalent in Cox’s Bazar, 
especially in refugee camps. 
Religious and social events 
threaten efforts to reduce 
transmission. Pharmacies and 

















J Clin Pathol. | 
Review 
 Summary of evidence for diagnoses 
of cases and to aid laboratories and 
healthcare workers to select the best 







14.04.2020 Proteomics of 
SARS-CoV-2-





 This study identifies the host 
cell pathways modulated by 
SARS-CoV-2 infection and 
show that inhibition of these 
pathways prevent viral 
replication in human cells 
14.05.2020 Hydroxychloroquine 
in patients with 
mainly mild to 
moderate 
coronavirus 
disease 2019: open 
label, randomised 
controlled trial 
BMJ | Article 
 Hospitalised adult patients 
with mainly mild to moderate 
persistent COVID-19 who 
received hydroxychloroquine 
plus standard of care did not 
clear the virus more quickly 
than those receiving standard 
of care alone in this 
multicentre, open label 
randomised controlled trial in 
China, 11 to 29 February 
2020 
 Adverse events were high in 
hydroxychloroquine 
recipients than in non-
recipients 
4 
Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type Author(s) 
15.05.2020 Health inequity during the COVID-
19 pandemic: a cry for ethical 
global leadership 










14.05.2020 Global coordination on cross-
border travel and trade measures 
crucial to COVID-19 response 
The Lancet | Comment Kelley Lee 
Catherine Z 
Worsnop 
Karen A Grepin 
Adam Kamradt-
Scott 
14.05.2020 An appeal for practical social 
justice in the COVID-19 global 
response in low-income and 
middle-income countries 
The Lancet Global 







Madhukar Pai et 
al.  
14.05.2020 Leveraging Africa’s preparedness 
towards the next phase of the 
COVID-19 pandemic 
The Lancet Global 
Health | Comment 
Madikay 
Senghore 






Iruka N Okeke 
14.05.2020 COVID-19 response in the Middle 
East and north Africa: challenges 
and paths forward 
The Lancet Global 




14.05.2020 Dozens of coronavirus drugs are in 
development – what happens 
next? 
Nature | News Heidi Ledford 
14.05.2020 Machine learning can help get 
COVID-19 aid to those who need it 
most 
Nature | World View Joshua 
Blumenstock 
13.05.2020 Health in a time of COVID-19 – 
how and where do we start 
strengthening health systems? 
Health Policy and 
Planning | Blog 
Fiona Samuels 
Ana B. Amaya 
Dina Balabanova 
13.05.2020 How COVID-19 is changing the 
world: a statistical perspective 
from international agencies  
World Bank | Blog Haishan Fu 
12.05.20 Impact of international travel 
dynamics on domestic spread of 
2019-nCoV in India: origin-based 
risk assessment in importation of 
infected travellers 
Globalization and 
Health | Commentary 
Sachin S. 
Gunthe 
Satya S. Patra  
  
6 
Guidelines, Statements & Tools 
Publication 
Date 
Title/URL Source   Summary 
13.05.2020 COVID-19 and the 





 Rapid implementation of three 
recommended actions will be 
essential to ensure people and 
societies are better protected 
from the mental health impact of 
COVID-19 
 A study in Ethiopia in April 2020 
reported a 3-fold increase in the 
prevalence of symptoms of 
depression compared to 
estimates from before the 
epidemic 
 April 2020 Considerations and 
principles for 
shielding people at 
high risk of severe 
outcomes from 
COVID-19 
 SSHAP | 
Brief 
 Provides an overview of 
proposed approaches to 
shielding individuals at high risk 
of severe disease or death from 
COVID-19 in LMICs and 
considers feasibility, challenges 
and ways to mitigate them 
 Decisions on shielding must 
consider local socio-economic 
context, involve local actors and 
adapt in response to new 
evidence about the approach’s 
effectiveness, characteristics of 
COVID-19 and outbreak 
trajectories 
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PLoS CMMID Repository     
UNOCHA   Annals of 
Internal 
Medicine 
Norwegian Institute of Public 
Health 
    




Oxford Centre for Evidence-
based Medicine 
    





 HEART     
UNESCO   SAGE 
journals 
 UKRI     
UN WFP   JAMA  Evidence Aid     
GOARN    Bulletin 
of the 
WHO 
 NIH     
EPI-WIN           
World Bank           
Our World in 
Data 
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Online learning & events 





WHO Academy and 
WHO Info mobile 
applications 






















5 hours Johns Hopkins 






5 sessions 1h 30 International Initiative 











online brief with Dr 
David Nabarro 
Event 1h 4SD 
30.04.2020 Professor Chris 
Whitty’s Gresham 
lecture on COVID-19 
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Evidence Summary. Brighton, UK: Institute of Development Studies. 
Rapid review methodology 
The rapid daily search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa”) OR (“equity” OR “equities”) OR (“poverty”), restricted to 
articles published in the previous 2 to 3 days, in English. This is complemented by a search of the homepage of 
the following high-impact global health journals: The Lancet journals, New England Journal of Medicine, Nature, 
JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ Global Health, the PLoS journals and a Twitter 
search of their Twitter pages. A search also of preprints from bioRxiv and medRxiv. Please note that papers that 
have not been peer-reviewed are highlighted in red. All primary research papers that relate to the primary and 
secondary impacts of the COVID-19 response in LMICs, and disease control and health system responses are 
included. Articles related to tackling the secondary impacts on other sectors are not included. Additional 
commentaries, opinions, and commissioned pieces are selected based on relevance. 
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
  
13 
About this report 
This daily COVID-19 health evidence summary (HES) is based on 3 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Department for 
International Development (DFID) and its partners in support of pro-poor programmes. 
It is licensed for non-commercial purposes only. K4D cannot be held responsible for 
errors, omissions or any consequences arising from the use of information contained in 
this health evidence summary. Any views and opinions expressed do not necessarily 
reflect those of DFID, K4D or any other contributing organisation.  
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